

## **AMB-FUBINACA & Related Compounds – Background**

### **What is AMB-FUBINACA?**

The drug AMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamido)-3-methylbutanoate) is a synthetic cannabinoid. It was first synthesized by Pfizer in 2009, along with numerous other related compounds. It is also known as FUB-AMB and MMB-FUBINACA. Other related synthetic cannabinoids in the Fubinaca family include AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, APINACA, ADB-CHMINACA, MDMB-CHMIINACA, and many others. These cannabinoids usually have similar parent chains that make up their chemical structure. They are designed to mimic the effects of delta-9-tetrahydrocannabinol (THC) contained in marijuana.

AMB-FUBINACA, and its related compounds, act as an agonist on the cannabinoid receptors in the central nervous system. Potential side effects of these synthetic cannabinoids include decreased body temperature, decreased or irregular heart rate, agitation, drowsiness, unresponsiveness, and lightheadedness.

### **What is it used for?**

Pfizer was working on developing a synthetic cannabinoid to treat pain in cancer patients, as synthetic cannabinoids may be more likely to ease pain without the effects of THC (i.e., producing a high in the user). During the clinical trials, Pfizer discontinued their research into properties of the drug. Currently, there are no approved medical uses in humans for AMB-FUBINACA or its related compounds.

### **Why is it dangerous?**

The US National Drug Early Warning System (NDEWS) released 2016 data from the Drug Enforcement Agency (DEA) indicating that 37 different types of synthetic cannabinoids had been identified in 2016; AMB-FUBINACA accounted for the majority (almost 23%) of those identifications. By spring 2017, AMB-FUBINACA accounted for 51% of all synthetic cannabinoids identified. Synthetic cannabinoids are the most rapidly growing class of designer recreational drugs. With this rise in new cannabinoids, users may be unaware of what they are consuming.

Research has shown that AMB-FUBINACA is up to 85 times more potent than THC. Side effects associated with long-term use or large doses include psychosis, delirium, cardiotoxicity, seizures, hypothermia and death.

### **Fatalities and treatment**

In July 2016, a medical emergency in New York involved 33 people adversely affected by AMB-FUBINACA. Among those 33, 18 people were hospitalized. Fatalities caused by FUBINACA-related compounds have occurred in Europe, with 29 deaths recorded between 2014 and 2016 as a result of MDMB-CHMIINACA overdoses. Currently, there are no treatments to reverse an overdose of synthetic cannabinoids; symptoms can only be managed with supportive treatment.

### **AMB-FUBINACA and the law**

Many drugs in the FUBINACA family are classified as a Schedule II drugs in the Canadian Controlled Drugs and Substances Act. Possession and trafficking of a Schedule II drug are both punishable by a maximum of 5 years imprisonment; production or exportation of schedule II drug is punishable by a maximum of lifetime imprisonment.

## References

- Adams, A. J., Banister, S. D., Irizarry, L., Trecki, J., Schwartz, M., & Gerona, R. (2016). "Zombie" outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. *New England Journal of Medicine*, 376(3).
- Banister, S. D., Moir, M., Stuart, J., Kevin, R. C., Wood, K. E., Longworth, M., ... & Connor, M. (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. *ACS chemical neuroscience*, 6(9), 1546-1559.
- Buchler, I. P., Hayes, M. J., Hegde, S. G., Hockerman, S. L., Jones, D. E., Kortum, S. W., Rico, J. G., ... & Wu, K. K. (2009). Indazole derivatives as CB1 receptor modulators unflagging work flagging work or and their preparation and use in the treatment of CB1-mediated diseases. *Patent: WO/2009/106982*.
- Drug Enforcement Agency (2017). *Emerging threat report: Second quarter 2017*. Retrieved from: <https://ndews.umd.edu/sites/ndews.umd.edu/files/emerging-threat-report-2017-quarter-2.pdf>
- Controlled Drugs and Substances Act, SC 1996, c 19. Retrieved from: <http://laws-lois.justice.gc.ca/eng/acts/C-38.8>
- Gurney, S.M.R., Scott, K.S., Kacinko, S.L., Presley, B.C., & Logan, B.K. (2014). Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs; *Forensic Science Review*, 26(1), 53-77.
- European Monitoring Centre for Drugs and Drug Addiction (2016). *EMCDDA–Europol Joint Report on a new psychoactive substance: methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA)*, Joint Reports, Publications Office of the European Union: Luxembourg
- Head, J. M. (2017). *Synthetic drug threats in the United States: 2017 update [PowerPoint slides]*. Retrieved from: <https://ndews.umd.edu/sites/ndews.umd.edu/files/ndews-webinar-feb-15-2017-synthetic-drug-threats-jill-m-head-dea.pdf>
- Jones, J. D., Nolan, M. L., Daver, R., Comer, S. D., & Paone, D. (2017). Can naloxone be used to treat synthetic cannabinoid overdose? *Biological Psychiatry*, 81(7), e51-e52.
- Roberts, J. R. (2015). Synthetic cannabinoids: Treating toxicity, *Emergency Medicine News*, 37(8), 12-14.
- Shanks, K.G., Clark, W., & Behonick, G. (2016). Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. *Journal of Analytical Toxicology*, 40 (3), 236-239. doi: 10.1093/jat/bkv142

© 2017 Alberta Health Services. This material is protected by Canadian and other international copyright laws. All rights reserved. This material may not be copied, published, distributed or reproduced in any way in whole or in part without the express written permission of Alberta Health Services (please contact David O'Brien, Community, Seniors, Addiction & Mental Health at [patti.vandervelden@ahs.ca](mailto:patti.vandervelden@ahs.ca)). This material is intended for general information only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.

For more information about this document, contact Knowledge Exchange, Provincial Addiction and Mental Health, Alberta Health Services at [researchpartnership@ahs.ca](mailto:researchpartnership@ahs.ca). Updated: August 2017.